Abstract:We are investigating basic questions like why do Foxp3+ T-regulatory (Treg) cells have at least 3 nuclear complexes involving Hdac1 and Hdac2 (CoREST, Sin3, NuRD), and how can the inhibitory effects of Foxp3+ Tregs on host anti-tumor immune responses be targeted therapeutically? Here, we report on the immune functions of chromodomain-helicase-DNA-binding protein 4 (Chd4), a key enzyme of the nucleosome remodeling and deacetylase complex (NuRD) complex. TCGA analysis showed increased Chd4 expression and Foxp3+ Tregs within lung tumors, leading us to assess the effects of conditional gene deletion within Foxp3+ murine Tregs. Chd4 knockout led to systemic autoimmunity and death of mice within 3 weeks of life and RNAseq studies showed Chd4 loss led to derepression of ~1400 genes and repression of >700 further genes resulting in a Treg signature markedly different from conditional deletion of Hdac1, Hdac2 or Mbd2 in Treg cells. Chd4 is an intrinsically disordered therapeutic target without a defined structure outside its physiological cell environment. To date, no specific inhibitors targeting Chd4 have been developed. We have identified Ch41, a novel and potent inhibitor of Chd4, using a novel cellular target engagement platform. Transcriptomic and mass-spec investigations showed that Ch41 impaired thymic Treg function and iTreg development, led to decreased CNS2 demethylation within the Foxp3 locus, and significantly impaired growth of lung tumors and hepatocellular carcinomas in immunocompetent but not in immunodeficient C57BL/6 mice (p<0.01). Following Chd4 inhibitor therapy, intratumoral conventional T cells had increased activation and cytokine production (IL-2, IFN-g) compared to intratumoral T cells in control tumor-bearing mice but, perhaps unexpectedly, treated mice did not show histologic or biochemical evidence of autoimmunity. We conclude that while tumor associated Tregs have unique properties that include their increased suppressive activity compared to non-tumor associated Treg cells, they are also more susceptible than the latter and conventional T cells to newly developed therapeutic interventions, including targeting of the Chd4 chromodomain of the NuRD complex. Citation Format: Wayne W. Hancock, Liqing Wang, Martina Minisini, Eros di Giorgio, Ivan Babic, Elmar Nurmemmedov. Unexpected role of the NuRD component, Chd4, in Foxp3+ Treg cells and its relevance to tumor immunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2655.

Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction

Neuropilin-1 Identifies a New Subpopulation of TGF--Induced Foxp3<SUP>+</SUP> Regulatory T Cells With Potent Suppressive Function and Enhanced Stability During Inflammation

Ash1l and lnc-Smad3 coordinate Smad3 locus accessibility to modulate iTreg polarization and T cell autoimmunity

NR4A1 transcriptionally regulates the differentiation of stem-like CD8+ T cells in the tumor microenvironment

Transcriptional control of central T cell tolerance by NR4A family nuclear receptors

Induction and transcriptional regulation of the co-inhibitory gene module in T cells

NAC1 Modulates Autoimmunity by Suppressing Regulatory T Cell–mediated Tolerance

CTLA-4 expression by B-1a B cells is essential for immune tolerance

Nr4a1 Plays a Crucial Modulatory Role in Th1/Th17 Cell Responses and CNS Autoimmunity

Abstract 2655: Unexpected role of the NuRD component, Chd4, in Foxp3+ Treg cells and its relevance to tumor immunotherapy

CXXC-finger protein 1 associates with FOXP3 to stabilize homeostasis and suppressive functions of regulatory T cells

The transcription factor TOX is involved in the regulation of T-cell exhaustion in neuroblastoma

Different Aberrant Expression Pattern of Immune Checkpoint Receptor in Patients with T-NHL and NK/T-CL

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

Noc4L-Mediated Ribosome Biogenesis Controls Activation of Regulatory and Conventional T Cells.

Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity

BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells

NR4A1 Mediates NK‐cell Dysfunction in Hepatocellular Carcinoma Via the IFN‐γ/p‐STAT1/IRF1 Pathway

NR4A nuclear receptors restrain B cell responses to antigen when second signals are absent or limiting

Neurotrophic factor Neuritin modulates T cell electrical and metabolic state for the balance of tolerance and immunity

PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome